Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 801-821
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 72
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e62-e74
Closed Access | Times Cited: 43
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 697-718
Open Access | Times Cited: 37
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
Ayalew Tefferi, Maymona Abdelmagid, Giuseppe Gaetano Loscocco, et al.
American Journal of Hematology (2025)
Open Access | Times Cited: 3
Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification
Jürgen Thiele, H. M. Kvasnicka, Umberto Gianelli, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Tariq I. Mughal, Nicholas C.P. Cross, E. Padron, et al.
Haematologica (2015) Vol. 100, Iss. 9, pp. 1117-1130
Open Access | Times Cited: 98
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Ayalew Tefferi, Hassan B. Alkhateeb, Naseema Gangat
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e735-e746
Closed Access | Times Cited: 23
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 2, pp. 300-308
Closed Access | Times Cited: 9
Synthetic Approaches to the New Drugs Approved During 2022
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4376-4418
Closed Access | Times Cited: 9
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, et al.
Blood Advances (2024) Vol. 8, Iss. 6, pp. 1515-1528
Open Access | Times Cited: 8
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis
Giuseppe Gaetano Loscocco, Giada Rotunno, Francesco Mannelli, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 1, pp. 68-78
Open Access | Times Cited: 16
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
Ayalew Tefferi, Animesh Pardanani
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire Harrison, Ruben A. Mesa, Moshe Talpaz, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e729-e740
Closed Access | Times Cited: 6
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 5
Mutations, inflammation and phenotype of myeloproliferative neoplasms
Sylvie Hermouet
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
Andrea Duminuco, Elena Torre, Giuseppe A. Palumbo, et al.
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 5, pp. 176-189
Closed Access | Times Cited: 14
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study
Yi Zhang, Hu Zhou, Minghui Duan, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1588-1597
Open Access | Times Cited: 14
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus
Barbara Klencke, Rafe Donahue, Boris Gorsh, et al.
Future Oncology (2024) Vol. 20, Iss. 11, pp. 703-715
Open Access | Times Cited: 4
Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
Marko Lucijanić, Ivan Krečak, Ena Sorić, et al.
Life (2024) Vol. 14, Iss. 4, pp. 523-523
Open Access | Times Cited: 4
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Oncology and Therapy (2025)
Open Access
Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems
Yin-Yin Chang, Yu‐Hung Wang, Chao‐Hung Wei, et al.
Hematological Oncology (2025) Vol. 43, Iss. 1
Closed Access
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024
Martin Grießhammer, Haifa Kathrin Al‐Ali, Jan‐Niklas Eckardt, et al.
Annals of Hematology (2025)
Open Access
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
John O. Mascarenhas, Keri Maher, Raajit K. Rampal, et al.
Future Oncology (2025), pp. 1-7
Open Access
Page 1 - Next Page

Scroll to top